ReVessel Introduces AI-Driven Digital Twin of Human Blood for Personalized Medicine

ReVessel has unveiled a groundbreaking AI-driven platform that creates a digital twin of human blood, a first in the health-tech industry. This innovative technology simulates the hematologic and hemodynamic state of individuals in real time, transforming blood into a dynamic, encrypted data layer for personalized medical modeling. The platform's ability to integrate multi-omics, pharmacokinetics, and clinical indicators allows for customized simulations, moving beyond traditional one-size-fits-all approaches to treatment and transfusion decisions.

The core of ReVessel's technology is its digital twin engine, which uses AI to replicate an individual's blood dynamics instantly. This engine converts complex biological data into predictive insights, enabling healthcare providers to anticipate how blood will react under various conditions or treatments. With simulations delivered in under 200 milliseconds, clinicians can make quicker, more informed decisions at the point of care.

Designed for seamless integration, ReVessel's platform supports standard clinical data formats like EMR, FHIR, and OMOP, ensuring compatibility with existing healthcare systems without the need for extensive infrastructure changes. Currently in the early stages of development, ReVessel is not yet available commercially but is working closely with clinical advisors and research institutions to refine and validate its platform. The company is also exploring partnerships with investors and collaborators to further its mission of revolutionizing personalized blood management.